En Carta Diagnostics raises €5 million to bring at-home molecular tests for Lyme disease and STIs to market
En Carta Diagnostics, a Paris-based DeepTech startup developing a new generation of molecular diagnostics for use at home, has announced the first closing of €5 million in financing. This closing includes €3 million in equity led by Blue Forest Ventures with participation from Ring Capital and exist
<p>En Carta Diagnostics, a Paris-based DeepTech startup developing a new generation of molecular diagnostics for use at home, has announced the first closing of €5 million in financing. This closing includes €3 million in equity led by Blue Forest Ventures with participation from Ring Capital and exist</p>